{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.56","value":"-8.9"},{"groupId":"OG001","spread":"19.13","value":"-8.7"},{"groupId":"OG002","spread":"15.83","value":"-5.4"}]}],"title":"Cycle 4 - approximately Month 4 (n=113,121,127)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.64","value":"-9.0"},{"groupId":"OG001","spread":"23.25","value":"-9.7"},{"groupId":"OG002","spread":"20.81","value":"-6.0"}]}],"title":"Cycle 7 - approximately Month 7 (n=96,109,112)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.00","value":"-7.9"},{"groupId":"OG001","spread":"23.85","value":"-7.1"},{"groupId":"OG002","spread":"18.79","value":"-5.4"}]}],"title":"Cycle 10 - approximately Month 10 (n=85,91,95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.91","value":"-7.2"},{"groupId":"OG001","spread":"24.90","value":"-8.8"},{"groupId":"OG002","spread":"21.84","value":"-6.3"}]}],"title":"Cycle 13 - approximately Month 13 (n=72,73,82)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.87","value":"-10.5"},{"groupId":"OG001","spread":"25.79","value":"-5.9"},{"groupId":"OG002","spread":"20.67","value":"-3.3"}]}],"title":"Cycle 16 - approximately Month 16 (n=62,51,62)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}